bexarotene has been researched along with toremifene in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Baidas, S; Cohen, R; Demetri, GD; DeMichele, A; Dickler, M; Esteva, FJ; Glaspy, J; Hayes, DF; Hortobagyi, GN; Hutchins, L; Laufman, L; Osborne, CK; Tripathy, D; Winer, E; Yocum, RC | 1 |
1 review(s) available for bexarotene and toremifene
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for bexarotene and toremifene
| Article | Year |
|---|---|
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Breast Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Tetrahydronaphthalenes; Thyroid Hormones; Toremifene; Treatment Outcome | 2003 |